Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here
Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period
Cipla Share Price Live Updates: Cipla's beta value highlights consistent performance
Cipla Share Price Live Updates: Cipla's Price Movement Today
Q4 Results This Week: Bharti Airtel, HPCL, Dixon, among 200 companies reporting numbers
As many as 200 companies, including Nifty 50 names such as Bharti Airtel, Cipla, JSW Steel and Power Grid, and multiple F&O and cash market names such as UPL, Canara Bank, Indian Hotels etc. will be reporting their March quarter results this week. Here's a look at the complete list:
Q4 Results Next Week: Bharti Airtel, HAL, Tata Motors, Cochin Shipyard, Premier Energies, ITC Hotels And More
PVR Inox, Dixon Technologies, Dr Reddys Laboratories, Tata Steel, Cipla, JSW Steel and NCC, among others will declare earnings from May 11 and 16.
Cipla Share Price Live Updates: Cipla's Solid Monthly Return
Cipla Share Price Live Updates: Cipla's six-month beta reflects stability
Cipla Share Price Live Updates: Cipla's Trading Volume Insights
Cipla Share Price Live Updates: Cipla's Recent Trading Close
Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosol
Pharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks a significant milestone for Cipla, reinforcing its leadership in the respiratory segment. The approval enhances Cipla's US portfolio, offering a therapeutic equivalent to a key branded medication.
Cipla jumps nearly 5% after USFDA nod for generic Ventolin inhaler
Cipla shares rose after USFDA approved its first AB rated generic Ventolin HFA inhaler, to launch in US by first half FY27, targeting a $1.5 billion market.
Alkem Labs CEO Vikas Gupta may exit company
Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to depart in the coming months. Gupta joined Alkem from Cipla and has a strong background in the Indian pharmaceutical market.